Summary
This 8-K/A filing from Colgate-Palmolive (CL) serves as an amendment, primarily to provide updated financial reporting information and clarify segment reporting changes. The most significant update for investors relates to the earnings for the quarter ended September 30, 2024, as announced in a press release dated October 25, 2024. While the earnings details themselves are incorporated by reference via Exhibit 99.1, the filing confirms that this information has been officially communicated. Furthermore, the company has realigned its skin health business reporting structure, effective July 1, 2024. This change consolidates previously dispersed skin health operations into the North America reportable operating segment. It's crucial to note that this realignment, while affecting segment reporting, does not alter the company's overall consolidated financial results or position. The company has provided recast historical segment information (Exhibit 99.2) for consistency with the new structure, allowing investors to analyze performance on a comparable basis.
Key Highlights
- 1Amendment to a previous 8-K filing.
- 2Includes press release dated October 25, 2024, announcing Q3 2024 earnings (incorporated by reference).
- 3Reports a realignment of the skin health business reporting structure effective July 1, 2024.
- 4Skin health business previously in Europe segment now reported within North America segment.
- 5No impact on consolidated results of operations or financial position due to segment realignment.
- 6Recast historical segment information provided for periods from 2021 through Q2 2024.
- 7Recast information is for consistency and does not constitute a restatement of previously issued financial statements.